ZyVersa Therapeutics Inc.的封面图片
ZyVersa Therapeutics Inc.

ZyVersa Therapeutics Inc.

制药业

Weston,FL 942 位关注者

Restoring Health, Transforming Lives Through Innovation

关于我们

ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging two licensed proprietary product platforms to develop pharmaceutical products that address unmet medical needs in the areas of renal and inflammatory diseases. Lead renal candidate, Phase 2a-ready VAR 200, mediates removal of excess intracellular lipids in the kidney’s filtration system that contribute to kidney damage leading to end-stage kidney disease. Lead anti-inflammatory drug candidate, inflammasome ASC inhibitor (IC 100), blocks initiation and perpetuation of damaging inflammation that’s pathogenic in a multitude of inflammatory diseases.

网站
http://www.zyversa.com
所属行业
制药业
规模
11-50 人
总部
Weston,FL
类型
私人持股
创立
2014
领域
Drug Development、Orphan Disease、Nephrology和Immunology

地点

  • 主要

    2200 N. Commerce Parkway, Suite 208

    US,FL,Weston,33326

    获取路线
  • Four Tower Bridge, 200 Barr Harbor Drive

    Suite 400

    US,Pennsylvania,West Conshohocken,19428

    获取路线

ZyVersa Therapeutics Inc.员工

动态

相似主页

查看职位

融资